Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of S-268019-b versus ChAdOx1 nCoV-19 for COVID-19 vaccination
jRCT2051210151Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268019-b primary vaccination arm with ChAdOx1 nCoV-19 primary vaccination arm (2 arms). Primary endpoints: SARS-CoV-2 neutralizing antibody titer after primary vaccination, SARS-CoV-2 neutralizing antibody titer after booster vaccination and 2 more. Started Jan 2022; status: completed.
02
Drugs
S-268019-bChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051210151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210151.